This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Abicipar Pegol

Allergan plc

Drug Names(s): AGN150998, MP0112, MP-0112, anti-VEGF DARPin, AGN-150998, AGN 150998

Description: AGN-150998 (MP0112) is a DARPin-based anti-angiogenic drug. AGN-150998 is an antagonist of Vascular Endothelial Growth Factor A (VEGF-A) that inhibits all relevant subtypes of VEGF-A with very high potency (IC50 of < 10 pM). AGN-150998 was shown to have a very long half-life in the eye (> 6 days).

DARPins are one of several classes of protein therapeutics being developed by companies that seek to reproduce the high selectivity and binding affinity of antibody therapeutics in a non-antibody structural scaffold. Potential advantages offered by these new protein scaffolds relative to traditional antibodies include:

  • Inexpensive production in non-mammalian cell culture, typically E. coli;
  • Improved product homogeneity and ease of purification;
  • Improved penetration into tissues due to dramatically reduced molecular weight;
  • Ability to target well-established targets while circumventing broad antibody patent estates.

Deal Structure: Allergan and Molecular Partners
In May 2011, Allergan and Molecular Partners announced that they have entered into a license agreement for AGN-150998 (MP0112) for the treatment of retinal diseases. Under the agreement, Allergan obtains exclusive global rights for AGN-150998 (MP0112) for ophthalmic indications. The parties will work together during Phase IIb development and Allergan will be responsible for Phase III development and commercialization activities. Molecular Partners will receive an up-front payment of USD $45 million and is further entitled to receive additional payments of up to an aggregate of USD $375 million upon meeting certain development, regulatory and sales milestones. In addition, Molecular Partners will receive tiered double-digit royalties on any future sales of AGN-150998 (MP0112).

Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will...See full deal structure in Biomedtracker

Partners: Molecular Partners AG

Abicipar Pegol News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug